Caricamento...
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Focal Adhesion Kinase (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune checkpoint inhibitors. However, which patients are most likely to benefit from FAK inhibitors, and what the optimal FAK/immunotherapy combinations are, is currently unknown. We ident...
Salvato in:
| Pubblicato in: | eLife |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
eLife Sciences Publications, Ltd
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6974352/ https://ncbi.nlm.nih.gov/pubmed/31959281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.48092 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|